Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer.

ABSTRACT:

Background

Immunotherapy has emerged as a promising treatment strategy in malignant tumors. Inhibitors and neutralizing antibodies targeted PD-1 or PD-L1 show improved clinical outcomes in advanced non-small cell lung cancers (NSCLCs). Previous studies concluded that PD-1 was mainly expressed on activated T cells, B cells and other immune cells. Recently, two studies suggested that PD-1 could be detected in the tumor cells of melanoma and hepatocellular carcinoma. Tumor-endogenous PD-1 in NSCLCs has not been reported at present. Thus, we intended to explore the expression and prognostic relevance of tumor-endogenous PD-1 in NSCLCs.

Methods

We detected the PD-1 expression in fresh tumor samples and tumor slices by flow cytometer and immunohistochemical analysis respectively.

SUBMITTER: Gan F 

PROVIDER: S-EPMC8841543 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature